The pharmaceutical and agrochemical giant has intensified its restructuring, slashing 12,000 full-time jobs—nearly double the figure announced earlier this year. The stock promptly tumbled over 4% to €26.61. Management aims to streamline decision-making by cutting administrative layers, reducing the workforce from 100,000 to around 90,000. Meanwhile, legal battles over glyphosate have ballooned, with provisions for Roundup lawsuits now at $7.4 billion, including an additional €1.2 billion set aside in July. The Q2 net loss surged to €199 million, six times higher than the previous year, far exceeding analysts’ expectations of €75 million.
Mixed Signals Amid Cost Pressures
Operationally, Bayer showed resilience: revenue hit €10.74 billion, meeting forecasts, while adjusted EBITDA matched guidance at €2.11 billion. The company maintained its full-year outlook of €44–46 billion in revenue and €9.2–9.7 billion in adjusted EBITDA. However, currency effects erased €600 million in growth, and free cash flow plummeted 90% to €100 million. The pharmaceuticals division, led by strong performances from key drugs, partially offset losses from patent expirations. Despite raising its 2025 revenue forecast, Bayer’s net debt of €33.3 billion remains a lingering concern.
Ad
Bayer Stock: Buy or Sell?! New Bayer Analysis from December 26 delivers the answer:
The latest Bayer figures speak for themselves: Urgent action needed for Bayer investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from December 26.
Bayer: Buy or sell? Read more here...
